Table 3.

Development of tuberculosis, herpes zoster, and lymphoma according to ruxolitinib exposure in patients with MF

	N	PMF: SMF	Male: female	Follow-up duration, median (range), mo	No. of patients with tuberculosis*	No. of patients with herpes zoster*	No. of patients with lymphoma*
Patients exposed to ruxolitinib	192	161:31	125:67	16.2 (1.0-28.8)†	5 (2.6%)	22 (11.5%)	1 (0.5%)
					2 male subjects and 3 female subjects	13 male subjects and 9 female subjects	A 54-year-old female patient
					Median age, 68 y (range, 44-77 y)	Median age, 66.5 y (range, 40-86 y)	Diagnosed with B-cell non-Hodgkin lymphoma
					Median time from ruxolitinib to tuberculosis, 12.9 mo (range, 1.34-16.38 mo)	Median time from ruxolitinib to herpes zoster, 6.92 mo (range, 0-23.55 mo)	Time from ruxolitinib to diagnosis of lymphoma, 6.2 mo
Patients not exposed to ruxolitinib	489	433:56	292:197	28.78 (1-113.8)‡	11 (2.3%)	40 (8.2%)	4 (0.8%)
					10 male subjects and 1 female subject	26 male subjects and 14 female subjects	3 male subjects and 1 female
					Median age, 76 y (range, 66-87 y)	Median age, 63 y (range, 27-83)	Median age: 71.5 y (range, 54-75 y)
					Median time from diagnosis of MF to tuberculosis, 19.9 mo (range, 2.3-88.5 mo)	Median time from diagnosis of MF to herpes zoster: 18.8 mo (range, 1.74-81.6 mo)	Median time from diagnosis of MF to lymphoma, 25.7 mo (range, 6.0-54.6 mo)

^*From 1 month after initiation of ruxolitinib (in ruxolitinib-exposed patients) or diagnosis of MF (in the ruxolitinib-nonexposed patients) to last follow-up or death.

^†From initiation of ruxolitinib to last follow-up or death.

^‡From diagnosis of PMF or SMF to last follow-up or death.